コンテンツへスキップ
Merck

911860

Sigma-Aldrich

NanoFabTx microfluidic - micro

device kit for synthesis of 1-5 μm particles

別名:

Microfluidic kit, Microparticle, NanoFabTx device kit, Nanoformulation

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12162002
UNSPSCコード:
41121811
NACRES:
NA.23

詳細

Microfludic device kit for synthesizing 1-5 μm microparticles

Kit components :

  • Microfluidic chip x 1
  • Tubings and accessories

品質水準

アプリケーション

advanced drug delivery

類似した製品をお探しですか? 訪問 製品比較ガイド

詳細

NanoFabTx Microfluidic - micro device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and accessories—a microfluidic platform to synthesize drug-encapsulating microparticles 1-5 μm in size. It is compatible with either a standard syringe pump (not included) or the Dolomite microfluidics system (not included). The device kit does not include reagents. NanoFabTx- micro reagent kits, like NanoFabTx PLGA-micro (Cat.No. 912220) provide the reagents for the synthesis of 1-5 μm PLGA microparticles.

アプリケーション

NanoFabTx Microfluidic - micro device kit is designed to work with the NanoFabTx- micro reagent kits for the synthesis of 1-5 μm particles (Cat.No. 912220) and can be used to create drug-encapsulated polymeric microspheres with narrow size-dispersity and consistent drug loading. Polymeric microparticles also can encapsulate larger biologics like proteins, mRNA, and DNA, in addition to drugs and small molecules, and may serve as vehicles for targeted delivery and controlled release. Microfluidic-based synthesis is a powerful tool in drug development for fabricating size-controlled drug-delivery particles, enabling scalable synthesis of particles and rapid formulation screening. In contrast to nanoprecipitation or solvent-displacement methods, microfluidic technologies have several advantages including enhanced reproducibility, less consumption of expensive reagents, and superior scalability.

特徴および利点

  • Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
  • Optimized to make monodisperse microparticles of any size between 1 and 5 μm
  • Facilitates simple optimization of drug encapsulation and loading efficiency in microparticles

法的情報

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Andrew Gdowski et al.
Journal of nanobiotechnology, 16(1), 12-12 (2018-02-13)
The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the parameters used in the original formulation must be
Samar Damiati et al.
Genes, 9(2) (2018-02-22)
Microfluidic devices present unique advantages for the development of efficient drug carrier particles, cell-free protein synthesis systems, and rapid techniques for direct drug screening. Compared to bulk methods, by efficiently controlling the geometries of the fabricated chip and the flow
Xuanyu Li et al.
Advanced drug delivery reviews, 128, 101-114 (2017-12-27)
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods.

資料

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™キットは、ナノ粒子・リポソームドラッグデリバリー製剤の迅速かつ十分に制御された合成のために最適化されています。薬物放出挙動が制御された、さまざまな治療薬化合物のカプセル化を行うことができます。

NanoFabTx™DDS製剤プラットフォームは、マイクロ粒子、ナノ粒子またはリポソーム製剤を容易に合成可能なキットです。NanoAssemblr®装置を用いたナノ製剤化事例をご紹介します。

NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)